Fernandes Ana Carolina Nl, Jorge Cristine H, Weatherall Mark, Ribeiro Isadora V, Wallace Sheila A, Hay-Smith E Jean C
Department of Health Sciences, Ribeirão Preto Medical School (FMRP), University of São Paulo, Ribeirão Preto, Brazil.
Department of Health Sciences, Ribeirão Preto Medical School (FMRP), Graduation Program in Rehabilitation and Functional Performance, University of São Paulo, Ribeirão Preto, Brazil.
Cochrane Database Syst Rev. 2025 Mar 11;3(3):CD009252. doi: 10.1002/14651858.CD009252.pub2.
Pelvic floor muscle training (PFMT), compared to no treatment, is effective for treating urinary incontinence (UI) in women. Feedback and biofeedback are additional resources that give women more information about their pelvic floor muscle contraction. The extra information could improve training performance by increasing capability or motivation for PFMT. The Committee on Conservative Management from the 7th International Consultation on Incontinence states that the benefit of adding biofeedback to PFMT is unclear. This review is an update of a Cochrane review last published in 2011.
The primary objective was to assess the effects of PFMT with feedback or biofeedback, or both, for UI in women. We considered the following research questions. Are there differences in the effects of PFMT with feedback, biofeedback, or both versus PFMT without these adjuncts in the management of stress, urgency or mixed UI in women? Are there differences in the effects of feedback versus biofeedback as adjuncts to PFMT for women with UI? Are there differences in the effects of different types of biofeedback?
We searched the Cochrane Incontinence Specialised Register (searched 27 September 2023), which includes searches of CENTRAL, MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO ICTRP as well as handsearching of journals and conference proceedings, and the reference lists of relevant articles.
We included only randomised controlled trials (RCTs), cluster-RCTs and quasi-RCTs in women with UI. We excluded studies that recruited women with neurological conditions, who were pregnant or less than six months postpartum. Eligible studies made one of the following comparisons: PFMT plus feedback versus PFMT alone, PFMT plus biofeedback versus PFMT alone, PFMT plus feedback or biofeedback versus PFMT alone, PFMT plus feedback versus PFMT plus biofeedback, and one type of biofeedback versus another.
Two review authors independently assessed studies for eligibility, extracted data onto a prepiloted form, and assessed risk of bias using RoB 1. We used the GRADE approach to assess the certainty of evidence in each comparison by outcome. Our primary outcome was lower urinary tract symptom-specific quality of life. We pooled data using a standardised mean difference (SMD). Secondary outcomes were leakage episodes in 24 hours (mean difference (MD)), leakage severity (MD), subjective cure or improvement (odds ratio (OR)), satisfaction (OR), and adverse events (descriptive summary).
We included 41 completed studies with 3483 women. Most (33 studies, 3031 women) investigated the effect of PFMT with biofeedback versus PFMT alone. Eleven studies were at low risk of bias overall, 27 at unclear risk of bias, and three at high risk. Only one study reported leakage severity, with no usable data. Comparison 1. PFMT with feedback versus PFMT alone: one eligible study reported no outcome of interest. Comparison 2. PFMT with biofeedback versus PFMT alone: there was little or no difference in incontinence quality of life (SMD 0.07 lower, 95% confidence interval (CI) 0.18 lower to 0.05 higher; 11 studies, 1169 women; high-certainty evidence). Women randomised to biofeedback had 0.29 fewer leakage episodes in 24 hours versus PFMT alone (MD 0.29 lower, 95% CI 0.42 lower to 0.16 lower; 12 studies, 932 women; moderate-certainty evidence), but this slight reduction in leakage episodes may not be clinically important. Women in biofeedback arms report that there is probably little to no difference in cure or improvement (OR 1.26, 95% CI 1.00 to 1.58; 14 studies, 1383 women; moderate-certainty evidence) but may report greater satisfaction with treatment outcomes (OR 2.41, 95% CI 1.56 to 3.7; 6 studies, 390 women; low-certainty evidence). None of these outcomes were blinded. Eight studies (711 women) assessed severe adverse events but reported that there were no events. Comparison 3. PFMT with feedback or biofeedback versus PFMT alone: a single study contributed very-low certainty evidence regarding leakage episodes in 24 hours, subjective cure or improvement, and satisfaction. Comparison 4. PFMT with feedback versus PFMT with biofeedback: the evidence is very uncertain about any difference in effect between biofeedback versus feedback for incontinence-related quality of life. Not only is the evidence certainty very low, the confidence interval is very wide and there could be a more than small effect in favour of biofeedack or feedback (SMD 0.14 lower, 95% CI 0.56 lower to 0.28 higher; 2 studies, 91 women; very-low certainty evidence). There may be fewer leakage episodes in 24 hours for women receiving biofeedback verus feedback but the difference may not be clinically important and the evidence certainty is low (MD 0.28 lower, 95% CI 0.62 lower to 0.07 higher; 2 studies, 120 women; low-certainty evidence). There were no data for subjective cure, improvement or satisfaction. One study measured adverse events and none were reported. Comparison 5. PFMT with biofeedback versus PFMT with another type of biofeedback: five studies assessed this comparison, with individual studies contributing data for separate outcomes. There was low- or very-low certainty evidence about the benefits of one type of biofeedback versus another for leakage episodes in 24 hours or subjective cure or improvement, respectively. One study reported adverse events from two of nine women receiving electromyography biofeedback versus six of 10 receiving pressure biofeedback.
AUTHORS' CONCLUSIONS: PFMT with biofeedback results in little to no difference in incontinence quality of life. The addition of biofeedback to PFMT likely results in a small unimportant difference in leakage episodes in 24 hours, and likely little to no difference in patient-reported cure or improvement. Satisfaction may increase slightly for PFMT with biofeedback, based on low-certainty evidence. Five of the 33 studies in this comparison collected information about adverse events, and four reported none in either group. Adverse events reported by women using biofeedback seemed related to using a vaginal or rectal device (e.g. discomfort with device in place, vaginal discharge). The other comparisons had few, small studies, and low- to very low-certainty evidence for all outcomes. None of the studies reported any severe adverse events.
与不进行治疗相比,盆底肌训练(PFMT)对治疗女性尿失禁(UI)有效。反馈和生物反馈是额外的手段,能让女性获得更多关于盆底肌收缩的信息。这些额外信息可通过提高PFMT的能力或动机来改善训练效果。第七届国际尿失禁咨询会保守治疗委员会指出,在PFMT中添加生物反馈的益处尚不清楚。本综述是对2011年发表的一篇Cochrane综述的更新。
主要目的是评估PFMT联合反馈或生物反馈,或两者同时使用,对女性尿失禁的影响。我们考虑了以下研究问题。在女性压力性、急迫性或混合性尿失禁的管理中,PFMT联合反馈、生物反馈或两者同时使用与不使用这些辅助手段的PFMT在效果上是否存在差异?对于患有尿失禁的女性,作为PFMT辅助手段的反馈与生物反馈在效果上是否存在差异?不同类型的生物反馈在效果上是否存在差异?
我们检索了Cochrane尿失禁专业注册库(检索日期为2023年9月27日),其中包括对CENTRAL、MEDLINE、MEDLINE在研、MEDLINE Epub Ahead of Print、ClinicalTrials.gov、世界卫生组织国际临床试验注册平台的检索,以及对期刊和会议论文集的手工检索,还有相关文章的参考文献列表。
我们仅纳入了针对患有尿失禁女性的随机对照试验(RCT)、整群RCT和半随机对照试验。我们排除了招募患有神经系统疾病、怀孕或产后不到六个月女性的研究。符合条件的研究进行了以下比较之一:PFMT加反馈与单纯PFMT、PFMT加生物反馈与单纯PFMT、PFMT加反馈或生物反馈与单纯PFMT、PFMT加反馈与PFMT加生物反馈,以及一种生物反馈与另一种生物反馈。
两位综述作者独立评估研究的 eligibility,将数据提取到预先设计好的表格中,并使用RoB 1评估偏倚风险。我们采用GRADE方法按结局评估每个比较中证据的确定性。我们的主要结局是下尿路症状特异性生活质量。我们使用标准化均数差(SMD)合并数据。次要结局包括24小时漏尿次数(均数差(MD))、漏尿严重程度(MD)、主观治愈或改善(比值比(OR))、满意度(OR)和不良事件(描述性总结)。
我们纳入了41项完成的研究,共3483名女性。大多数(33项研究,3031名女性)研究了PFMT联合生物反馈与单纯PFMT的效果。11项研究总体偏倚风险较低,27项偏倚风险不明确,3项偏倚风险较高。只有一项研究报告了漏尿严重程度,但没有可用数据。比较1. PFMT联合反馈与单纯PFMT:一项符合条件的研究未报告感兴趣的结局。比较2. PFMT联合生物反馈与单纯PFMT:在尿失禁生活质量方面几乎没有差异(SMD低0.07,95%置信区间(CI)低0.18至高0.05;11项研究,1169名女性;高确定性证据)。随机接受生物反馈的女性24小时漏尿次数比单纯PFMT少0.29次(MD低0.29,95%CI低0.42至低0.16;12项研究,932名女性;中等确定性证据),但漏尿次数的这种轻微减少可能在临床上并不重要。接受生物反馈的女性报告治愈或改善方面可能几乎没有差异(OR 1.26,95%CI 1.00至1.58;14项研究,1383名女性;中等确定性证据),但可能对治疗结局的满意度更高(OR 2.41,95%CI 1.56至3.7;6项研究,390名女性;低确定性证据)。这些结局均未设盲。八项研究(711名女性)评估了严重不良事件,但报告无事件发生。比较3. PFMT联合反馈或生物反馈与单纯PFMT:一项研究提供了关于24小时漏尿次数、主观治愈或改善以及满意度的极低确定性证据。比较4. PFMT联合反馈与PFMT联合生物反馈:关于生物反馈与反馈在尿失禁相关生活质量影响上的任何差异,证据非常不确定。不仅证据确定性非常低,置信区间非常宽,而且可能存在有利于生物反馈或反馈的较大效应(SMD低0.14,95%CI低0.56至高0.28;2项研究,91名女性;极低确定性证据)。接受生物反馈的女性24小时漏尿次数可能比接受反馈的女性少,但差异可能在临床上并不重要且证据确定性低(MD低0.28,95%CI低0.62至高0.07;2项研究,120名女性;低确定性证据)。没有关于主观治愈、改善或满意度的数据。一项研究测量了不良事件,未报告任何事件。比较5. PFMT联合生物反馈与PFMT联合另一种生物反馈:五项研究评估了此比较,个别研究为单独结局提供了数据。关于一种生物反馈与另一种生物反馈在24小时漏尿次数或主观治愈或改善方面的益处,证据确定性低或极低。一项研究报告了接受肌电图生物反馈的9名女性中有2名出现不良事件,而接受压力生物反馈的10名女性中有6名出现不良事件。
PFMT联合生物反馈在尿失禁生活质量方面几乎没有差异。在PFMT中添加生物反馈可能会使24小时漏尿次数产生微小的不重要差异,并且在患者报告的治愈或改善方面可能几乎没有差异。基于低确定性证据,PFMT联合生物反馈可能会使满意度略有提高。在此比较中的33项研究中有5项收集了关于不良事件的信息,4项报告两组均无不良事件。使用生物反馈的女性报告的不良事件似乎与使用阴道或直肠设备有关(例如,设备放置时的不适、阴道分泌物)。其他比较的研究较少且规模较小,所有结局的证据确定性都很低或极低。没有研究报告任何严重不良事件。